DAX23.273 +0,8%Est505.542 +0,5%MSCI World4.343 -0,1%Top 10 Crypto11,78 +0,5%Nas22.793 +2,3%Bitcoin75.471 +0,1%Euro1,1527 +0,1%Öl62,76 +0,4%Gold4.095 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 NVIDIA 918422 Novo Nordisk A3EU6F RENK RENK73 DroneShield A2DMAA Siemens Energy ENER6Y Lufthansa 823212 Deutsche Telekom 555750 Alphabet A (ex Google) A14Y6F HENSOLDT HAG000 TKMS thyssenkrupp Marine Systems TKMS00 BASF BASF11 Amazon 906866 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX steigt -- Wall Street freundlich -- Novo Nordisk scheitert bei Alzheimer-Studie -- Alphabet, TKMS, D-Wave, DroneShield, Siemens Energy, Rheinmetall & Co., DHL, Bayer, Lufthansa, NEL im Fokus
Top News
Ausblick: HP legt Quartalsergebnis vor Ausblick: HP legt Quartalsergebnis vor
Bitcoin-Holding-Aktien wie Strategy und Metaplanet: Kapitalabflüsse in Milliardenhöhe drohen Bitcoin-Holding-Aktien wie Strategy und Metaplanet: Kapitalabflüsse in Milliardenhöhe drohen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Eli Lilly Aktie

Kaufen
Verkaufen
Eli Lilly Aktien-Sparplan
927,90 EUR +4,20 EUR +0,45 %
STU
1.073,46 USD +13,18 USD +1,24 %
BTT
Eli Lilly jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.869,86 Mrd. EUR

KGV65,91Div. Rendite0,67%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN858560

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS5324571083

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolLLY

Eli Lilly Aktien News

DatumMeistgelesen
FOX BusinessEli Lilly cuts prices for Zepbound weight-loss drug again
MotleyFoolWhy Eli Lilly Stock Popped Today
BenzingaEli Lilly Expands Zepbound Vial Options, Lowers Prices For 2.5 mg, 5 Mg Doses
MarketWatchEli Lilly cuts price of weight-loss drug Zepbound as competition heats up
EN, Eli LillyLilly launches additional Zepbound vial doses and offers new savings for self-pay patients
PR NewswireLilly launches additional Zepbound vial doses and offers new savings for self-pay patients
MotleyFoolWall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
ZacksEli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
MotleyFoolDigging Into What Hershey and Eli Lilly Told Investors
EN, Eli LillyLilly to participate in TD Cowen's 45th Annual Health Care Conference
PR NewswireLilly to participate in TD Cowen's 45th Annual Health Care Conference
ZacksThe Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell
ZacksTop Stock Reports for Apple, Eli Lilly & Shopify
MotleyFoolGLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
BenzingaEli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
ZacksEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
EN, Eli LillyMost patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
EN, Eli LillyMost patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
PR NewswireMost patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
MotleyFoolEli Lilly (LLY) Q4 2024 Earnings Call Transcript
MotleyFoolWhy Eli Lilly Stock Popped on Thursday
Financial TimesEli Lilly expects to beat profit forecasts on obesity drug demand
Seattle TimesDiabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
BenzingaEli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
ZacksEli Lilly (LLY) Q4 Earnings and Revenues Top Estimates
EN, Eli LillyLilly reports full Q4 2024 financial results and provides 2025 guidance
PR NewswireLilly reports full Q4 2024 financial results and provides 2025 guidance
BenzingaEli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
BenzingaEli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?
BenzingaWhat To Expect When Eli Lilly Reports Q4 Earnings On Thursday?
ZacksThe Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb
ZacksEli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?
BenzingaEli Lilly Unusual Options Activity
ZacksEli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ZacksEli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
BenzingaAssessing Eli Lilly: Insights From 7 Financial Analysts
ZacksInvestors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
MotleyFoolMove Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
MotleyFoolWhy Eli Lilly Stock Topped the Market Today
PR NewswireLilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.